ClinicalTrials.gg
CompletedNCT01510327PLATINUM PKUpdated Mar 26, 2019Results posted

PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)

A Phase 3 interventional study of PROMUS Element Everolimus-Eluting Coronary Stent System and Aspirin in Coronary Artery Disease, sponsored by Boston Scientific Corporation. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Boston Scientific Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies testing aspirin in Coronary Artery Disease — 8 open to participants now, 9 under way, 1 of them phase 3. Aspirin · Coronary Artery Disease.

Enrollment
45th of 53
22 · median 200
Started
2009
with 6 others
Phase 3
7 of 53
1 open now
Registered
21st of 53
by date
Lead sponsor
3 of 53
Boston Scientific Corporation

Among the 53 studies testing aspirin in Coronary Artery Disease, this one is the 45th largest by enrollment, is one of 7 that started in 2009, is one of 7 in phase 3, and was the 21st registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

8 of the 53 studies testing aspirin in Coronary Artery Disease are open now, in 6 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aspirin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. The lesions are located in vessels that are average-sized.

Read the detailed description

The wide-spread use of drug-eluting stents (DES) has evolved as standard of care in de novo lesions. The proposed study will evaluate the safety and effectiveness of PROMUS Element for the treatment of de novo atherosclerotic lesions in native coronary arteries. The study design is consistent with the draft guidance for industry titled, "Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies" (March 2008).

During the trial, thienopyridines must be administered according to the 2007 American College of Cardiology (ACC)/American Heart Association (AHA)/Society for Cardiovascular Angiography and Interventions (SCAI) guidelines, which recommended that clopidogrel (75 mg daily) or ticlopidine (250 mg twice daily) be prescribed after stent implantation for at least 6 months in all patients, and for at least 12 months in patients who are not at high risk of bleeding. For sites in the United States, the use of prasugrel is not allowed as part of the PLATINUM Clinical Trial. For sites in other countries, prasugrel may be prescribed according to its approved dosing in countries in which it is available. For patients taking aspirin daily a loading dose is recommended; for patients who have not been taking aspirin daily, aspirin must be administered as a loading dose. Patients continue to take aspirin indefinitely to reduce the risk of thrombosis.

This PLATINUM Pharmacokinetics (PK) study is a sub-trial associated with the PLATINUM Workhorse Randomized Controlled Trial, which is registered under NCT00823212. PLATINUM PK was designed to evaluate the elution of everolimus from the PROMUS Element everolimus-eluting stent.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • drug-eluting stents
  • DES
  • atherosclerotic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient must be at least 18 years of age
  • Patient (or legal guardian) understands study requirements and treatment procedures and provides written before any study-specific tests or procedures are performed
  • For patients less than 20 years of age enrolled at a Japanese site, patient and patient's legal representative must provide written informed consent before any study-specific tests or procedures are performed
  • Patient is eligible for percutaneous coronary intervention (PCI)
  • Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris
  • Patient is an acceptable candidate for coronary artery bypass grafting (CABG)
  • Patient has a (LVEF) >=30% as measured within 30 days prior to enrollment
  • Patient is willing to comply with all protocol-required follow-up evaluations

Angiographic Inclusion Criteria (visual estimate):

  • Target lesion must be a de novo lesion located in a native coronary artery with a visually estimated reference vessel diameter (RVD) >=2.50 mm and \<=4.25 mm. Target lesion length must measure (by visual estimate) \<=24 mm. Target lesion must be in a major coronary artery or branch with visually estimated stenosis >=50% and \<100% with Thrombolysis in Myocardial Infarction (TIMI) flow >1.

Exclusion criteria

Exclusion Criteria:

  • Patient has clinical symptoms and/or (ECG) changes consistent with acute myocardial infarction (MI)
  • Patient has had a known diagnosis of recent MI (ie, within 72 hours prior to index procedure) and has elevated enzymes at time of index procedure as follows.

    • Patients are excluded if any of the following criteria are met at time of the index procedure.

      • If creatine kinase-myoglobin band(CK-MB) >2× (ULN), the patient is excluded regardless of CK Total.
      • If CK-MB is 1-2× ULN, the patient is excluded if the CK Total is >2× ULN.
    • If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at time of index procedure.

      • Troponin >1× ULN with at least one of the following.
      • Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (eg, >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);
      • Development of pathological Q waves in the ECG; or
      • Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling/randomizing the patient.

  • Patient has received an organ transplant or is on a waiting list for an organ transplant
  • Patient is receiving or scheduled to receive chemotherapy within 30 days before or after index procedure
  • Patient is receiving oral or intravenous therapy (ie, inhaled are not excluded) or has known life-limiting immunosuppressive or disease (eg, , systemic lupus erythematosus, but not including diabetes mellitus)
  • Patient is receiving chronic (>=72 hours) anticoagulation therapy (eg, heparin, coumadin) for indications other than acute coronary syndrome
  • Patient has count \<100,000 cells/mm3 or >700,000 cells/mm3
  • Patient has white blood cell (WBC) count \<3,000 cells/mm3
  • Patient has documented or suspected liver disease, including laboratory evidence of hepatitis
  • Patient is on dialysis or has known renal insufficiency (ie, estimated \<50 ml/min by the Cockcroft Gault formula, or [(140-age)*lean body weight (in kg)]/[plasma creatinine (mg/dl)*72])
  • Patient has history of bleeding diathesis or coagulopathy or will refuse blood transfusions
  • Patient has had a cerebrovascular accident (CVA) or (TIA) within past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol
  • Target vessel(s) or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to index procedure
  • Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by visual estimate) with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to index procedure
  • Non-target vessel or side branch has been treated with any type of PCI (eg, balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to index procedure
  • Planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter immediately prior to stent placement
  • Planned PCI or CABG after index procedure
  • Patient previously treated at any time with coronary intravascular brachytherapy
  • Patient has a known allergy to the study stent system or protocol-required concomitant medications (eg, stainless steel, platinum, cobalt, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated
  • Patient has active peptic ulcer or active gastrointestinal (GI) bleeding
  • Patient has one of the following.

    • Other serious medical illness (eg, cancer, congestive heart failure) that may reduce to less than 24 months
    • Current problems with substance abuse (eg, alcohol, cocaine, heroin, etc.)
    • Planned procedure that may cause non-compliance with protocol or confound data interpretation
  • Patient is participating in another drug or device clinical trial that has not reached its primary endpoint
  • Patient intends to participate in another investigational drug or device clinical trial within 12 months after index procedure
  • Patient with known intention to procreate within 12 months after index procedure (Women of who are sexually active must agree to use a reliable method of from the time of screening through 12 months after the index procedure.)
  • Patient is a woman who is pregnant or nursing (A pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
  • Patient has more than 2 target lesions, or more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure

Angiographic Exclusion Criteria (visual estimate):

  • Target lesion meets any of the following criteria:

    • Aorto-ostial location (ie, lesion located within 5 mm of ostium by visual estimate)
    • Left main location
    • Located within 5 mm of origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery by visual estimate
    • Located within a saphenous vein graft or arterial graft
    • Will be accessed via a saphenous vein graft or arterial graft
    • Involves a side branch >=2.0 mm in diameter by visual estimate
    • Involves a side branch \<2.0 mm in diameter by visual estimate that has a clinically significant stenosis at the ostium
    • TIMI flow 0 (total occlusion) or TIMI flow 1 prior to wire crossing
    • Excessive tortuosity proximal to or within the lesion
    • Extreme angulation proximal to or within the lesion
    • Target lesion and/or target vessel proximal to the target lesion is moderately to severely calcified by visual estimate
    • Restenotic from previous intervention
    • Thrombus, or possible thrombus, present in target vessel
  • Non-target lesion to be treated during the index procedure meets any of the following criteria:

    • Located within the target vessel
    • Located within a bypass graft (venous or arterial)
    • Left main location
    • Chronic total occlusion
    • Involves a complex bifurcation (eg, bifurcations requiring treatment with more than 1 stent)
    • Restenotic from previous intervention
  • Patient has unprotected left main coronary artery disease (>50% diameter stenosis)
  • Patient has protected left main coronary artery disease and a target lesion in the LAD or LCX
  • Patient has an additional clinically significant lesion(s) in target vessel for which an intervention within 12 months after the index procedure is likely to be required
  • Patient has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate) Note: Multiple focal stenoses will be considered as a single lesion if they can be completely covered with 1 stent.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    PROMUS Element

    Patients who received the PROMUS Element everolimus-eluting stent (EES) implanted using standard percutaneous coronary intervention (PCI) technique. Total loaded dose of everolimus per stent is dependent on stent size and in this study the administered dose ranged from 60.1 µg to 138.6 µg per stent. Note that the total dose of everolimus administered to a patient is based on the number of stents received and the size of the stent(s). The total dose received per patient ranged from 60.1 µg to 197.8 µg.

    Device: PROMUS Element Everolimus-Eluting Coronary Stent System · Drug: Aspirin · Drug: Thienopyridine

Interventions

  • DevicePROMUS Element Everolimus-Eluting Coronary Stent System

    PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).

  • Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.

  • Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.

    Also known as: A brand name for clopidogrel is PLAVIX., A brand name for ticlopidine is TICLID.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Everolimus Blood Concentration (Cmax)

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

Secondary outcomes

  1. Area Under the Concentration Versus Time Curve (AUC 0-t) Everolimus

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent; t is the last time at which concentration can be quantified

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

  2. Area Under the Concentration Versus Time Curve (AUC 0-24), Everolimus

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

  3. Area Under the Concentration Versus Time Curve (AUC 0-infinity) Everolimus

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point), 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after implantation of the last study stent.

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

  4. Time of Occurrence of Maximum Everolimus Concentration (Tmax)

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

  5. Terminal Phase Half-life (t1/2) Everolimus

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point), at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent.

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

  6. Total Blood Clearance - Everolimus (CL)

    Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point), 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent.

    Time frame: Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours

  7. All Death

    Number of participants no longer alive

    Time frame: 6 months

  8. Myocardial Infarction (MI) Related to the Target Vessel

    New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase (CK) MB or troponin \>normal; if no new Q-waves total CK levels \>3× normal (peri-percutaneous coronary intervention \[PCI\]) or \>2× normal (spontaneous) with elevated CK-MB or troponin \>3× normal (peri-PCI) or \>2× normal (spontaneous) plus at least one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5× normal

    Time frame: 6 months

  9. Target Vessel Revascularization (TVR)

    TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.

    Time frame: 6 months

  10. Target Lesion Revascularization (TLR)

    TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.

    Time frame: 6 months

  11. Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition

    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

    Time frame: 24 hours

  12. Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

    Time frame: >24 hours-30 days

  13. Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

    DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

    Time frame: >30 days-1 year

07

Results

Posted Apr 5, 2012

Participant flow

From October 9, 2009 to February 9, 2010 there were 11 patients enrolled at 2 investigative sites in the United States and 11 patients enrolled at 3 sites in Japan. All enrolled patients received a PROMUS Element study stent.

Participant flow — Overall Study
MilestonePROMUS Element
Started22
Completed22
Not completed0

Outcome measures

PrimaryMaximum Observed Everolimus Blood Concentration (Cmax)

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · ng/mL
Maximum Observed Everolimus Blood Concentration (Cmax)
ng/mLEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Maximum Observed Everolimus Blood Concentration (Cmax)0.71 ± 0.090.67 ± 0.150.91 ± 0.20
SecondaryArea Under the Concentration Versus Time Curve (AUC 0-t) Everolimus

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent; t is the last time at which concentration can be quantified

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · ng*hr/mL
Area Under the Concentration Versus Time Curve (AUC 0-t) Everolimus
ng*hr/mLEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Area Under the Concentration Versus Time Curve (AUC 0-t) Everolimus7.27 ± 4.976.45 ± 5.2610.87 ± 7.36
SecondaryArea Under the Concentration Versus Time Curve (AUC 0-24), Everolimus

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · ng*hr/mL
Area Under the Concentration Versus Time Curve (AUC 0-24), Everolimus
ng*hr/mLEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Area Under the Concentration Versus Time Curve (AUC 0-24), Everolimus6.83 ± 2.036.14 ± 1.109.51 ± 0.64
SecondaryArea Under the Concentration Versus Time Curve (AUC 0-infinity) Everolimus

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point), 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after implantation of the last study stent.

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · ng*hr/mL
Area Under the Concentration Versus Time Curve (AUC 0-infinity) Everolimus
ng*hr/mLEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Area Under the Concentration Versus Time Curve (AUC 0-infinity) Everolimus19.26 ± 11.6912.95 ± 2.0560.74 ± 25.95
SecondaryTime of Occurrence of Maximum Everolimus Concentration (Tmax)

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point) and at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · hours
Time of Occurrence of Maximum Everolimus Concentration (Tmax)
hoursEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Time of Occurrence of Maximum Everolimus Concentration (Tmax)0.47 ± 0.030.62 ± 0.230.52 ± 0.09
SecondaryTerminal Phase Half-life (t1/2) Everolimus

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point), at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent.

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · Hours
Terminal Phase Half-life (t1/2) Everolimus
HoursEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Terminal Phase Half-life (t1/2) Everolimus34.19 ± 20.8122.83 ± 7.20136.06 ± 62.08
SecondaryTotal Blood Clearance - Everolimus (CL)

Venous blood draw up to 24 hours prior to implantation of the first study stent (predose time point), 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours after completion of implantation of the last study stent.

Time frame:
Predose <24 hours; post dose at 30 minutes, 1, 2, 4, 6, 12, 24, 48, and 72 hours
Reported as:
Mean · L/h
Total Blood Clearance - Everolimus (CL)
L/hEverolimus Dose of 95.4 µgEverolimus Dose of 102.4 µgEverolimus Dose of 138.6 µg
Total Blood Clearance - Everolimus (CL)6445 ± 39248044 ± 12762511 ± 1073
SecondaryAll Death

Number of participants no longer alive

Time frame:
6 months
Reported as:
Number · percentage of participants who died
All Death
percentage of participants who diedPROMUS Element
All Death0.0
SecondaryMyocardial Infarction (MI) Related to the Target Vessel

New Q-waves in ≥2 leads lasting ≥0.04 sec with creatine kinase (CK) MB or troponin \>normal; if no new Q-waves total CK levels \>3× normal (peri-percutaneous coronary intervention \[PCI\]) or \>2× normal (spontaneous) with elevated CK-MB or troponin \>3× normal (peri-PCI) or \>2× normal (spontaneous) plus at least one of the following: ECG changes indicating new ischemia (new ST-T changes, left bundle branch block), imaging evidence of new loss of viable myocardium, or new regional wall motion abnormality. Similar for MI diagnosis post coronary artery bypass graft with CK-MB or troponin \>5× normal

Time frame:
6 months
Reported as:
Number · percentage of participants
Myocardial Infarction (MI) Related to the Target Vessel
percentage of participantsPROMUS Element
Myocardial Infarction (MI) Related to the Target Vessel0.0
SecondaryTarget Vessel Revascularization (TVR)

TVR is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis ≥50% by quantitative coronary angiography in the target vessel, including the target lesion.

Time frame:
6 months
Reported as:
Number · percentage of participants
Target Vessel Revascularization (TVR)
percentage of participantsPROMUS Element
Target Vessel Revascularization (TVR)0.0
SecondaryTarget Lesion Revascularization (TLR)

TLR is any ischemia-driven repeat percutaneous intervention to improve blood flow of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion.

Time frame:
6 months
Reported as:
Number · percentage of participants
Target Lesion Revascularization (TLR)
percentage of participantsPROMUS Element
Target Lesion Revascularization (TLR)0.0
SecondaryDefinite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition

DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

Time frame:
24 hours
Reported as:
Number · percentage of participants
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition
percentage of participantsPROMUS Element
Definite + Probable Stent Thrombosis (ST) Rate Based on Academic Research Consortium (ARC) Definition0.0
SecondaryDefinite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

Time frame:
>24 hours-30 days
Reported as:
Number · percentage of participants
Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition
percentage of participantsPROMUS Element
Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition0.0
SecondaryDefinite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition

DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: \>24 hours to 30 days post; late ST: \>30 days to 1 year post; Very late ST: \>1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days).

Time frame:
>30 days-1 year
Reported as:
Number · percentage of participants
Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition
percentage of participantsPROMUS Element
Definite + Probable Stent Thrombosis Rate Based on Academic Research Consortium (ARC) Definition0.0

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PROMUS Element—2/22 (9.1%)9/22 (40.9%)
Most frequent serious events
Most frequent serious events
EventPROMUS Element
Gastritis erosiveGastrointestinal disorders1/22
Vascular pseudoaneurysmInjury, poisoning and procedural complications1/22
Synovial cystMusculoskeletal and connective tissue disorders1/22
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/22
Deep vein thrombosisVascular disorders1/22
Most frequent other events
Most frequent other events
EventPROMUS Element
Catheter site haematomaGeneral disorders4/22
Angina pectorisCardiac disorders3/22
Back painMusculoskeletal and connective tissue disorders2/22
Non-cardiac chest painGeneral disorders2/22

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PROMUS Element
<=18 years0
Between 18 and 65 years13
>=65 years9
Age, Continuous
Age, Continuous(years)PROMUS Element
Mean64.6 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)PROMUS Element
Female4
Male18
Region of Enrollment
Region of Enrollment(participants)PROMUS Element
United States11
Japan11
Cardiac History
Cardiac History(Participants)PROMUS Element
Previous Percutaneous Coronary Intervention (PCI)9
Previous Coronary Artery Bypass Graft (CABG)2
Previous Myocardial Infarction (MI)4
Stable Angina15
Unstable Angina2
Silent Ischemia5
History of Multivessel Disease9
Cardiac History - Left Ventricular Ejection Fraction
Cardiac History - Left Ventricular Ejection Fraction(Percent (of blood emptied))PROMUS Element
Mean59.64 ± 10.09
Height
Height(Centimeters)PROMUS Element
Mean165.57 ± 12.55
Weight
Weight(Kilograms)PROMUS Element
Mean73.68 ± 19.60

10 further baseline measures are reported on the registry.

08

Study locations

5 sites
  • Medical Center of the Rockies (Loveland)
    Loveland, Colorado 80538, United States
  • Cardiac & Vascular Research Center of Northern Michigan
    Petoskey, Michigan 49770, United States
  • Saiseikai Yokohama-City Eastern Hospital
    Yokohama City, Kanagawa-ken, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo-to, Japan
  • Sakakibara Heart Institute, Japan Research Promotion Society for Cardiovascular Diseases
    Fuchu-shi, Tokyo, Japan
09

References and documents

Individual participant data

Plan to share: Undecided — The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html).

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Feb 2010 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2012, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2011
First posted
Jan 16, 2012
Start
Oct 2009
Primary completionActual
Feb 2010
CompletionActual
May 2015
Results first posted
Apr 5, 2012
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01510327
Responsible party
Sponsor
First posted
Jan 16, 2012
Start date
Oct 2009
Primary completion
Feb 2010
Completion
May 2015
Results posted
Apr 5, 2012
Last update
Mar 26, 2019

Study contacts

Peter M. Maurer, MPH
study director · Boston Scientific Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aspirin · Thienopyridine

Start the discussion